Valeant is on track to pay down more than US$5bn of its debt ahead of its February 2018 target.
Valeant Pharmaceuticals left its full year earnings guidance unchanged
Outgoing Smith & Nephew chief executive Olivier Bohuon said third quarter revenue was in line with its expectations
The UK healthcare cost regulator has approved GSK's gene therapy for so-called 'bubble boy' syndrome while the US FDA has approved its shingles vaccine
The company placed 100 mln new ordinary shares of 0.025p each at a price of 0.7p per share
Summit remains on track to report initial results of its Phase II trial of ezutromid treatment for duchenne muscular dystrophy in the first quarter of 2018
Genedrive's COO is stepping down after three years in the role
Summit Therapeutics said it is preparing to enter Phase III of clinical trials for ridinilazole next year